Genmab — September 2018

[Plimsoller]

God morgen

[bibob]

God morgen.

[JKY_VH]

God morgen, så er der en uge til, at forhåbentlig stærke recepttal offentliggøres.

[bibob]

Ja , de må meget gerne overraske til den gode side.

[JKY_VH]

ja bestemt bibob,så vidt jeg husker var augusttallene gode sidste år;-)

[jkj]

Godmorgen Husk MS i aften kl. 20.15 der bliver sikkert en del informationer og stemningen som der skal tolkes på.

[bibob]

Har nogen hørt om første patient er behandlet i 1 Line i EU. ??

[bibob]

Efter godkendelsen.

[E_L]

study to use daratumumab, labeled with Zirconium-89 (89Zr ) through deferoxamine (DFO), known as 89Zr-DFO-daratumumab, for PET imaging of multiple myeloma https://clinicaltrials.gov/ct2/show/NCT03665155

[E_L]

ASCLEPIOS studies set back to 'recruiting' in clinicaltrials, where Novartis previously said they were fully recruited; who can explain why they would do that? https://clinicaltrials.gov/ct2/history/NCT02792231?A=17&B=18&C=merged

[Plimsoller]

They forgot something/someone. It happens to me all the time

[E_L]

[Bulder]

Even more mysterious: No of patients lowered from 956(actual!) to 900(anticipated). Obviously they can't count.

[E_L]

oktober 10-12 we will see 2 presentations/abstracts on Ofa at the Multiple Sclerosis summit in Berlin http://www.professionalabstracts.com/ectrims2018/iplanner/#/search

[gentogen]

Det ligner, at de gentager fejlen fra 11 maj registreringen. Mystisk...

[gentogen]

I øvrigt er ingen klinikker noteret som rekrutterende, så formodentlig bare en (gentagen) fejl

[Bulder]

Been through all locations. Only one location in Germany has resumed recuitment.

[Bulder]

Jo, een i Tyskland gentogen

[Bulder]

Novartis Investigative Site
[Recruiting]
Unterhaching, Germany, 82008

[Bulder]

Abstracts will be published on sept 26. But don't think there will be any results, only baseline characteristics